Document Detail


Advanced Waldenström's macroglobulinemia: usefulness of Morel's scoring system in establishing prognosis.
MedLine Citation:
PMID:  15710594     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
New treatments for patients with Waldenstrom's macroglobulinemia (WM) have necessited the development of prognostic indices. Using a sample of 92 patients with refractory or relapsing WM treated in a randomized trial, we show that Morel's prognostic scoring system for patients at diagnosis is also effective in patients with advanced disease.
Authors:
Vincent Lévy; Pierre Morel; Raphaël Porcher; Sylvie Chevret; Eric Wattel; Véronique Leblond
Related Documents :
11971224 - Successful treatment of pure red cell aplasia with plasmapheresis in a patient with sys...
2611124 - Mucosal involvement in systemic and chronic cutaneous lupus erythematosus.
18306484 - Successful etanercept therapy for refractory sacroiliitis in a patient with ankylosing ...
3581694 - Systemic lupus erythematosus: follow-up study of 148 patients. i: classification, clini...
24696164 - Tumor necrosis factor beta (tnf-β) ncoi polymorphism is associated with multiple scler...
20430204 - Extracoporeal membrane oxygenation hybrid with thoratec ventricular-assist devices as d...
Publication Detail:
Type:  Letter; Randomized Controlled Trial    
Journal Detail:
Title:  Haematologica     Volume:  90     ISSN:  1592-8721     ISO Abbreviation:  Haematologica     Publication Date:  2005 Feb 
Date Detail:
Created Date:  2005-02-15     Completed Date:  2006-08-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0417435     Medline TA:  Haematologica     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  279-81     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antineoplastic Agents / pharmacology
Cohort Studies
Cyclophosphamide / administration & dosage
Doxorubicin / administration & dosage
Drug Therapy, Combination
Humans
Male
Middle Aged
Multivariate Analysis
Prednisone / administration & dosage
Prognosis
Time Factors
Vidarabine / analogs & derivatives,  therapeutic use
Waldenstrom Macroglobulinemia / diagnosis*,  therapy*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 21679-14-1/fludarabine; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 5536-17-4/Vidarabine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lack of receptor activator of nuclear factor-kB ligand (RANKL) expression and functional production ...
Next Document:  Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood.